AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEXALIS THERAPEUTICS LTD

0.011

0.000

Volume:- -

Turnover:- -

Market Cap:2.78M

PE:-1.46

High:0.011

Open:0.011

Low:0.011

Close:0.011

52wk High:0.039

52wk Low:0.010

Shares:253.04M

Float Shares:63.39M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:--

ROA:-86.71%

PB:-2.93

PE(LYR):-1.46

Loading ...

Overview Company News Filings

Nexalis Therapeutics - Negotiations with Point8 Capital for Funding Have Ceased

THOMSON REUTERS

Nexalis Therapeutics Ltd-director Appointment/resignation

THOMSON REUTERS

Nexalis Therapeutics - Secures up to a$53 Mln Non-Dilutive Funding Across Three Sub-Facilities

THOMSON REUTERS

Nexalis Therapeutics - Signs Funding Partnership With Point8 Capital to Replace Existing Facility

THOMSON REUTERS

BRIEF-Nexalis Therapeutics Seeks Trading Halt

Nexalis Therapeutics Ltd - Trading Halt Requested Pending Announcement on Existing Debt Funding Facility

THOMSON REUTERS

Nexalis Therapeutics Ltd-Director Appointment/Resignation

THOMSON REUTERS

BRIEF-Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment

Nexalis Therapeutics Ltd - US Policy Market Advancement Supports Srx-25 Trd Treatment

THOMSON REUTERS

BUZZ-Australia's Nexalis Therapeutics gains most in over 6 months on trial approval

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NX1.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NX1.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NX1.AU\",,,,,undefined,":{"symbol":"NX1.AU","market":"AU","secType":"STK","nameCN":"NEXALIS THERAPEUTICS LTD","latestPrice":0.011,"timestamp":1787551920000,"preClose":0.011,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"NEXALIS THERAPEUTICS LTD","floatShares":63391198,"shares":253037323,"eps":-0.00751,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-24 16:12:00 AEST","open":0.011,"high":0.011,"low":0.011,"amount":0,"amplitude":0,"askPrice":0.011,"askSize":103045,"bidPrice":0.005,"bidSize":200000,"shortable":3,"etf":0,"ttmEps":-0.00751,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.011,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NX1.AU","preClose":0.01,"auctionPrice":0.01,"auctionVolume":100000,"auction":3,"marketStatus":"盘后竞价","timestamp":1783576811080}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NX1.AU\",,,,,undefined,":{"symbol":"NX1.AU","floatShares":63391198,"roa":"-86.71%","roe":"--","lyrEps":-0.00751,"shares":253037323,"dividePrice":0,"high":0.011,"amplitude":0,"preClose":0.011,"low":0.011,"week52Low":0.01,"pbRate":"-2.93","psRate":"2.82","week52High":0.039,"institutionHeld":0,"latestPrice":0.011,"committee":0.319936,"eps":-0.00751,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.00751,"open":0.011,"prevYearClose":0.024,"prevWeekClose":0.011,"prevMonthClose":0.011,"prevQuarterClose":0.012,"fiveDayClose":0.011,"twentyDayClose":0.011,"sixtyDayClose":0.023},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NX1.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NX1.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NX1.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649617807","title":"Nexalis Therapeutics - Negotiations with Point8 Capital for Funding Have Ceased","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649617807?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:48","pubTimestamp":1783302518,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4350CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NX1.AU","BK7096","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646123821","title":"Nexalis Therapeutics Ltd-director Appointment/resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2646123821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646123821?lang=en_us&edition=fundamental","pubTime":"2026-06-25 13:52","pubTimestamp":1782366778,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUE6WDW84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NX1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632236","title":"Nexalis Therapeutics - Secures up to a$53 Mln Non-Dilutive Funding Across Three Sub-Facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638632236?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:49","pubTimestamp":1779925747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4241BC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NX1.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632231","title":"Nexalis Therapeutics - Signs Funding Partnership With Point8 Capital to Replace Existing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638632231?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:49","pubTimestamp":1779925747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4241BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NX1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637743368","title":"BRIEF-Nexalis Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2637743368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637743368?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:39","pubTimestamp":1779406765,"startTime":"0","endTime":"0","summary":"BRIEF-Nexalis Therapeutics Seeks Trading Halt May 22 (Reuters) - Nexalis Therapeutics Ltd NX1.AX:TRADING HALT REQUESTED PENDING ANNOUNCEMENT ON EXISTING DEBT FUNDING FACILITYFurther company coverage: NX1.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y14A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NX1.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637687923","title":"Nexalis Therapeutics Ltd - Trading Halt Requested Pending Announcement on Existing Debt Funding Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2637687923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637687923?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:38","pubTimestamp":1779406736,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y14A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NX1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635327353","title":"Nexalis Therapeutics Ltd-Director Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635327353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635327353?lang=en_us&edition=fundamental","pubTime":"2026-05-13 11:10","pubTimestamp":1778641804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUE6Z2LTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NX1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629077753","title":"BRIEF-Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629077753","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629077753?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:28","pubTimestamp":1776907718,"startTime":"0","endTime":"0","summary":"BRIEF-Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD TreatmentApril 23 (Reuters) - Nexalis Therapeutics Ltd NX1.AX:US POLICY MARKET ADVANCEMENT SUPPORTS SRX-25 TRD TREATMENTFurther company coverage: NX1.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4151CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NX1.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629914071","title":"Nexalis Therapeutics Ltd - US Policy Market Advancement Supports Srx-25 Trd Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629914071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629914071?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:42","pubTimestamp":1776901328,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NX1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628220397","title":"BUZZ-Australia's Nexalis Therapeutics gains most in over 6 months on trial approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2628220397","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628220397?lang=en_us&edition=fundamental","pubTime":"2026-04-17 14:01","pubTimestamp":1776405719,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Nexalis Therapeutics gains most in over 6 months on trial approval** Shares of Australia's Nexalis Therapeutics NX1.AX rise as much as 21.1% to A$0.023, their biggest intraday pct gain since October 9, 2025** Stock touches its highest level since March 26** The clinical stage drug developer receives an approval from Australian health regulator Safety Review Committee  for a second trial for dosing of acute pain reliever, IRX-616a** Stock up 27.8% so far this week, set for its best week in over a year, if gains hold** Despite moves, stock down 4.2% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N4100C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NX1.AU","BK7007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}